Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
'Life changing' Alzheimer's drug is approved for use to reduce cognitive decline
A groundbreaking Alzheimer's drug, Leqembi, has been approved for use in the EU, targeting amyloid plaques. Initially blocked in July, the European Medicines Agency (EMA) approved it in August, recommending it for patients not in advanced stages. Developed by Eisai and Biogen, it's also approved in the US, Japan, and China. The drug is available in the UK under a different name, with potential side effects including ARIA. The EMA's approval is restricted to patients with lower risk of brain hemorrhage and fewer copies of the ApoE4 gene.
Europe Approves Leqembi For Alzheimer's Treatment
EMA approves Leqembi, first treatment for slowing Alzheimer's cognitive decline, reversing earlier rejection due to side effect concerns. Targeting early signs, it shows reduced cognitive decline in trials, but is limited to mild cases and those without ApoE4 gene risk. Developed by Eisai and Biogen, it has been approved globally, offering hope but not a cure, with potential to transform neurodegenerative disease treatment landscapes.
EU regulator backs Eisai-Biogen Alzheimer's drug after initial rejection
The article discusses the implementation of a Server-Side Rendering (SSR) service entry, identified by the file '/bundles/v1/views/latest/SSR-service-entry.c49d8207ea51fe4b43e4.js', within a web page structure.
EMA's CHMP finds path to Leqembi nod, backs three other new drugs
EMA’s CHMP reconsiders Leqembi approval, now positive if high-risk APOE4 patients are excluded. Initially opposed due to safety concerns, CHMP now backs approval for patients with zero or one APOE4 allele.
EU approves life changing 'important' Alzheimer's drug which can drastically slow onset
The EU approves Leqembi, a life-changing Alzheimer's drug, for patients not in advanced stages, after initial rejection due to risks like brain bleeding. The treatment, developed by Eisai and Biogen, is also approved in the UK, US, Japan, and China. It targets amyloid plaques and is available under different names in various countries, with a controlled release to manage risks.
Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe
The article discusses the use of SSR (Server-Side Rendering) in web development, focusing on its implementation and benefits.
Positive EMA Reversal Boosts Biogen's Leqembi Prospects Despite Challenges
Michael Yee of Jefferies maintains a Buy rating on Biogen (BIIB) with a $250.00 price target, citing positive developments for Biogen’s Alzheimer’s drug, Leqembi, in the European market. The European Medicines Agency’s approval recommendation, despite limitations, is seen as a significant market opportunity. Challenges include EU pricing and reimbursement processes, logistical issues, and the need for pipeline expansion, but the drug’s potential in specific patient groups supports the Buy recommendation.
Medical Devices Applying for Outpatient Medicare Supplemental Payments
CMS approved 40% of TPTP applications, including all FDA-designated breakthrough devices. Approved devices often lacked generalizability to Medicare beneficiaries, used surrogate markers, or did not meet all primary end points. Strengthening premarket clinical evidence requirements could improve clinical decision-making and care for Medicare beneficiaries.
European watchdog partially approves new Alzheimer's drug
The EMA partially approved Leqembi for mild cognitive impairment or mild dementia due to Alzheimer’s, limited to patients with one or no ApoE4 gene copy, to minimize brain bleeding risks. Leqembi, developed by Biogen and Eisai, targets early Alzheimer’s stages by clearing harmful proteins and has shown to reduce cognitive decline by 25%.
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in ...
Eisai and Biogen announce CHMP positive opinion for lecanemab, an Aβ monoclonal antibody for early Alzheimer’s disease, with the European Commission expected to make a final decision within 67 days.
© Copyright 2024. All Rights Reserved by MedPath